Ampliphi Biosciences Corp (APHB) 0.1850

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 12:53 PM

Ampliphi Biosciences Corp (APHB) 0.1850 $APHB

Acinetobacter Infections Therapeutics Pipeline Review, H1 2015 - 25 Companies & 43 Drug Profiles
M2 - Thu Jul 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w32xnp/acinetobacter) has announced the addition of the "Acinetobacter Infections - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acinetobacter Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acinetobacter Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Achaogen Inc. - Adenium Biotech ApS - AmpliPhi Biosciences Corporation - Aridis Pharmaceuticals LLC - AstraZeneca PLC - AvidBiotics Corp. - ConjuGon, Inc. - Emergent BioSolutions Inc. - FAB Pharma - LegoChem Biosciences, Inc - Melinta Therapeutics, Inc - Microbiotix, Inc. - Northern Antibiotics Oy - Nosopharm SAS - Novan, Inc. - Omnia Molecular Ltd. - Pfizer Inc. - Phylogica Limited - Sarepta Therapeutics, Inc. - Sealife PHARMA GMBH - Shionogi & Co., Ltd. - Synthetic Biologics, Inc. - Techulon, Inc. - Trana Discovery, Inc. - Vaxdyn, S.L. For more information visit http://www.researchandmarkets.com/research/w3...netobacter
SYN: 3.04 (+0.19), EBS: 33.85 (+1.10), SRPT: 30.02 (+0.66), PFE: 34.36 (+0.50), AZN: 66.45 (+1.90), AKAO: 6.27 (-0.07)

AmpliPhi Announces New Data Demonstrating Anti-Pseudomonal Bacteriophages Retained Biological Activity Following Nebulization
Business Wire - Fri Jun 12, 7:00AM CDT
AmpliPhi BioSciences Corporation (OTCQB: APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced new data demonstrating that bacteriophages remain active against Pseudomonas aeruginosa (P. aeruginosa) after nebulization. Data from this study, performed in collaboration with the Royal Brompton Hospital and Imperial College, UK, were presented at the 38th European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 46.54 (+1.02)

AmpliPhi Biosciences Corporation - Product Pipeline Review - 2014
M2 - Mon Jun 08, 7:23AM CDT
Product Pipeline Review - 2014

AmpliPhi to Present New Data on Biological Activity of Nebulized Anti-Pseudomonal Bacteriophage
Business Wire - Mon Jun 08, 7:03AM CDT
AmpliPhi BioSciences Corporation (OTCQB:APHB), a global leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that new data on the activity of P. aeruginosa bacteriophages after exposure to nebulizer systems applicable for use in future clinical trials will be presented at the European Cystic Fibrosis Conference, taking place in Brussels, Belgium from June 10-13.
XON: 46.54 (+1.02)

Global Leber Congenital Amaurosis (LCA) Therapeutics Pipeline Review, H1 2015 - 6 Companies & 7 Drug Profiles
M2 - Fri Jun 05, 6:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/zgpfl2/leber_congenital) has announced the addition of the "Leber Congenital Amaurosis (LCA) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Leber Congenital Amaurosis (LCA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Leber Congenital Amaurosis (LCA) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AmpliPhi Biosciences Corporation - Applied Genetic Technologies Corporation - BBB Therapeutics B.V. - ProQR Therapeutics N.V. - QLT Inc. - Spark Therapeutics, Inc. Drug Profiles - Gene Therapy to Activate Retinal Guanylyl Cyclase-1 for Leber Congenital Amaurosis-1 - QLT-091001 - QR-110 - rAAV2-CB-hRPE65 - Small Molecules for Inherited Retinal Diseases - SPK-RPE-65 - tgAAG-76 For more information visit http://www.researchandmarkets.com/research/zg...congenital
QLTI: 4.19 (+0.06), ONCE: 60.80 (+1.43)

AmpliPhi's manufacturing facility awarded cGMP certification to manufacture bacteriophage products for human use
M2 - Thu Jun 04, 3:44AM CDT
Antibacterial therapy company AmpliPhi BioSciences (OtherOTC:APHB) stated on Wednesday that its production facility in Ljubljana, Slovenia has passed the JAZMP's

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...